Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-MUC16/anti-CD3 bispecific antibody LBL-033

A bispecific monoclonal antibody containing one arm targeting human CD3, a T-cell surface antigen that is part of the T-cell receptor (TCR) complex, and two arms targeting the membrane-proximal domain of the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), with potential antineoplastic activity. Upon administration, anti-MUC16/anti-CD3 bispecific antibody LBL-033 binds to both T-cells and MUC16-expressing tumor cells, which cross-links the T cells to the tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against the MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed on a variety of cancer cell types. BY binding in a 2:1 ratio to MUC16 and CD3, LBL-033 improves aggregation in MUC16-overexpressing tumor cells while reducing the non-specific activation of CD3. This may improve efficacy and minimize potential systemic toxicity, such as cytokine release syndrome (CRS).
Synonym:anti-MUC16/CD3 bispecific antibody LBL-033
T-cell engager LBL-033
Code name:LBL 033
LBL-033
LBL033
Search NCI's Drug Dictionary